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Abstract  13 
Despite a substantially increased understanding of neuropathophysiology, insufficient functional 14 
recovery after peripheral nerve injury (PNI) remains a significant clinical challenge. Nerve 15 
regeneration following injury is dependent on Schwann cells, the supporting cells in the peripheral 16 
nervous system. Following nerve injury, Schwann cells adopt a pro-regenerative phenotype which 17 
supports and guides regenerating nerves. However, this phenotype may not persist long enough to 18 
ensure functional recovery. Tissue engineered nerve repair devices containing therapeutic cells that 19 
maintain the appropriate phenotype may help enhance nerve regeneration. The combination of gene 20 
and cell therapy is an emerging experimental strategy which seeks to provide the optimal 21 
environment for axonal regeneration and re-establishment of functional circuits. This review aims to 22 
summarise current pre-clinical evidence with potential for future translation from bench to bedside. 23 
 24 
 25 
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1. Introduction 26 
The wide distribution of peripheral nerves throughout the body, as well as their complexity, means 27 
that peripheral nerve injuries (PNIs) are frequently encountered in clinical practice [1]. Traumatic 28 
injuries, such as collisions, motor vehicle accidents, gunshot wounds, fractures and lacerations, are 29 
the most common causes of PNI [2]. Other causes include diabetes [3], cancer [4] and surgery [5]. 30 
PNIs occur in up to 5% of all trauma patients [6], with around 300 000 cases of PNI reported annually 31 
in Europe [7]. Retrospective studies have revealed that PNI is predominantly reported in young men 32 
of working age [8, 9], which has considerable social and economic impact [10]. PNIs can cause 33 
lifelong disability resulting from sensory, motor and/or autonomic deficits and intractable 34 
neuropathic pain [11].  35 
 36 
Peripheral nerves are unable to function without the structural and metabolic support provided by 37 
Schwann cells, the principal glial cells in the peripheral nervous system. Due to this close neuron-38 
Schwann cell interaction, an injury induces a response that involves both the neuron and the 39 
associated Schwann cells [12]. Following PNI, Schwann cells are reprogrammed to a phenotype 40 
specialised to promote repair. This reprogramming involves down-regulation of myelin genes, 41 
increased secretion of neurotrophic factors, elevation of cytokines, macrophage recruitment, myelin 42 
clearance and the formation of bands of Büngner which direct axons to their targets [13]. Injury-43 
induced Schwann cell reprogramming contributes to the intrinsic ability of peripheral nerves to 44 
spontaneously regenerate after injury [14]. Nevertheless, spontaneous peripheral nerve 45 
regeneration is nearly always incomplete and results in poor functional recovery [15]. Even with 46 
modern surgical techniques, only around 50% of surgical cases achieve restoration of function [11].  47 
 48 
The autologous nerve graft is the current clinical gold standard treatment for nerve damage which 49 
extends over a few centimetres in length [11]. It bridges the nerve gap and provides a physical 50 
scaffold over which axonal outgrowth may occur. Furthermore, it supplies Schwann cells necessary 51 
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for regeneration. However, it is also associated with several disadvantages. Autografts sacrifice a 52 
functioning nerve and may result in sensory loss, scarring and neuroma formation at the donor site. 53 
Additionally, size and fascicle mismatch, scarring and fibrosis may occur at the repair site, leading to 54 
poor regeneration [16]. This highlights the need for new therapeutic strategies that will maximize 55 
functional nerve regeneration and improve patient outcomes.  56 
 57 
With progress in regenerative medicine, and especially in tissue engineering, various nerve repair 58 
devices have been produced which attempt to circumvent the disadvantages of autologous nerve 59 
grafts. An emerging experimental strategy is the use of nerve repair devices which contain genetically 60 
modified stem cells. While this concept is still in its infancy in peripheral nerve repair, it holds great 61 
promise as clinical success with genetically modified stem cells has been achieved in other medical 62 
conditions. A prime example is the recent regulatory approval of StrimvelisTM, the first ex vivo 63 
autologous stem cell gene therapy to treat patients with severe combined immunodeficiency due to 64 
adenosine deaminase deficiency [17]. This remarkable advance implies that genetically modified 65 
stem cells are becoming a powerful clinically-relevant tool and may be applicable to translational 66 
research to promote peripheral nerve repair. This review aims to describe how the combination of 67 
gene therapy and stem cell-based tissue engineering may improve peripheral nerve regeneration 68 
following injury. 69 
 70 
2. Nerve repair devices  71 
Tissue engineering aims to produce tissue replacement material specifically tailored to promote 72 
repair and regeneration at the implant site [18]. In PNIs, the main goal of a nerve repair device is to 73 
bridge the nerve gap by joining the proximal and distal stumps and to recreate the naturally 74 
occurring cellular architecture [7].  Accordingly, a typical device consists of a scaffold as well as an 75 
array of cellular and/or molecular components to increase regeneration [15].  76 
 77 
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The materials used for nerve repair devices impart different physical properties that may influence 78 
repair [19]. Synthetic materials have advantages such as a defined chemical composition and 79 
mechanical properties which can be fine-tuned [20]. However, synthetic materials may lack sites for 80 
cellular adhesion. This may necessitate coating the surface of the scaffold with extracellular matrix 81 
(ECM) proteins, such as laminin or fibronectin, in order to provide a suitable environment for the 82 
cells [21]. The principal synthetic material used in early nerve repair devices was silicone [22]. 83 
Silicone is non-degradable and can provoke a foreign body response, leading to inflammation and 84 
scarring [19], and can potentially cause nerve compression [23]. Silicone is also biologically inert and 85 
may require surgical removal from the implant site after nerve repair occurs [24]. More recently, 86 
biodegradable synthetic polymers, including aliphatic polyesters, poly(phosphoesters), 87 
polyurethanes, piezoelectric polymers and some electrically conducting polymers have been 88 
investigated [15].  89 
 90 
Natural materials are often based on various components of the ECM such as collagen [25] and fibrin 91 
[26], but can also include other naturally derived materials such as alginate [27], silk [28] and 92 
chitosan [29]. They are an attractive source of material for tissue engineering as they are 93 
biocompatible, biodegradable and contain cell adhesion sites [20]. Despite their advantages, clinical-94 
grade sources of natural materials can be challenging to obtain and they tend to exhibit batch-to- 95 
batch variation. There are also limitations associated with controlling their mechanical properties. 96 
Additionally, biodegradation of natural materials may be difficult to control and may influence cell 97 
activity in unknown ways [20].  98 
 99 
3. Cell therapy 100 
Given the importance of Schwann cells following PNI, several authors have transplanted nerve repair 101 
devices seeded with Schwann cells resulting in improved regeneration in various animal models [30]. 102 
However, the sourcing of allogeneic Schwann cells may require the sacrifice of a functional nerve. 103 
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Additionally, Schwann cells have limited expansion capabilities in vitro so their use is likely to delay 104 
the provision of urgent treatment to the patient [31]. A key factor limiting the translation of nerve 105 
repair devices towards clinical application is the source of Schwann cells. There is a great interest in 106 
alternative cell sources, with stem cells representing the most promising avenue [32], primarily due 107 
to their self-renewal capacity and ability to differentiate into multiple lineages [33].  108 
 109 
Different sources of stem cells have a potential application in PNI [34, 35]. These include adipose 110 
derived stem cells [36], bone marrow stem cells [37], umbilical cord stem cells [38], skin-derived 111 
precursor cells [39], induced pluripotent stem cells [40] and embryonic stem cells [41]. Therapeutic 112 
benefits of stem cell therapy have been shown in several experimental models of peripheral nerve 113 
injury and the advantages and disadvantages of each stem cell source have been reviewed elsewhere 114 
[31, 42]. A significant challenge that remains is the identification and selection of the most suitable 115 
stem cell source to enhance regeneration. The ideal cell should be easily harvested from the patient 116 
to allow autologous therapy and prevent rejection, although allogeneic sources may also provide a 117 
good alternative if a detrimental immunological response can be avoided. It should be readily 118 
expandable in vitro [42], survive transplantation and engraft into the host tissues [34]. Further, it 119 
should exhibit similar phenotypic characteristics to Schwann cells and secrete factors required for 120 
peripheral nerve regeneration [42]. Additionally, in order to facilitate further opportunities to 121 
improve efficacy, it should be amenable to genetic modification. 122 
 123 
While a number of stem cell options are available for peripheral nerve repair, there is considerable 124 
advantage in ensuring that the implanted cells exhibit the best phenotype for supporting neuronal 125 
regeneration at the time of implantation and that this phenotype persists for the duration of the 126 
repair process. Stem cell differentiation and control of the repair phenotype has primarily been 127 
achieved by controlling environmental conditions, however, genetic modification provides an 128 
attractive alternative to optimise the behaviour of the therapeutic cells. 129 
6 
 
 130 
4. Gene therapy 131 
Gene therapy can be broadly defined as the treatment of a medical disorder by the introduction of 132 
genetic material into the appropriate cellular targets. The concept of gene therapy was initially 133 
conceived to correct the deleterious consequences of specific gene mutations associated with 134 
inherited diseases. However, gene therapy can also be applied to reprogramming cells in contexts 135 
other than inherited diseases [44], one of which is PNI. 136 
 137 
Following decades of research and limited efficacy, gene therapy has recently entered a ‘golden era’ 138 
with a range of high profile life-saving clinical trials for haematological [45], immunological [46, 47], 139 
ophthalmic [48] and neurological conditions [49, 50]. These advances may become relevant to 140 
translational research in gene therapy to promote peripheral nerve repair. 141 
 142 
Successful gene delivery to peripheral nerves and to Schwann cells has been reported with various 143 
viral vectors [51]. As previously described, Schwann cells play a central role in peripheral nerve 144 
regeneration as they are responsible for secreting growth-promoting molecules, guiding the 145 
regenerating axons toward target organs and myelinating regenerated axons. However, the pro-146 
regenerative properties of these cells can fade away after long periods of denervation [13]. Gene 147 
delivery to Schwann cells could be used to prevent down-regulation of genes associated with 148 
maintaining the repair phenotype and to keep the cells in their pro-regenerative state for a longer 149 
period of time. This makes gene therapy a potential adjuvant treatment in the reconstruction of 150 
peripheral nerves following injury. Additionally, overexpression of factors that selectively enhance 151 
regeneration of motor or sensory nerves may help to overcome the limited functional recovery after 152 
nerve injury and surgical repair, by enhancing appropriate regeneration towards muscle and sensory 153 
targets respectively [52].  154 
 155 
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The use of stem cells in the context of PNI may be enhanced by subjecting them to ex vivo genetic 156 
modification prior to seeding in nerve repair devices for transplantation. This involves obtaining cells 157 
from patients or donors followed by in vitro manipulation to enhance the therapeutic potential of 158 
the cell and subsequent transplantation into the patient. This approach has a number of advantages 159 
over in vivo gene therapy. The delivery of genetic material can be targeted to a specific cell type, i.e. 160 
the therapeutic cell, without affecting other cells in the body. Cells can be characterised in vitro for 161 
successful incorporation of the transgene and only those which show biological activity are then 162 
incorporated into nerve repair devices. Further, in the cases of autologous stem cell harvest, there is 163 
no risk of immunological rejection, as has been previously demonstrated [46, 47].  164 
 165 
4.1 Gene delivery systems 166 
Eurkaryotic cells present a number of barriers that prevent exogenous negatively charged genetic 167 
material from entering their genome. These barriers include the hydrophobic plasma membrane, the 168 
cytoplasm with associated nucleases and the nuclear envelope. This is problematic for gene therapy, 169 
which is highly dependent upon the efficient delivery of genes to cells. Therefore, gene delivery 170 
systems have been designed to facilitate this process, with viral vectors emerging as the most 171 
efficient approach [53]. Viral vectors are associated with a high rate of target cell transduction and 172 
transgene expression and recent developments have led to good safety profiles [54]. In fact, around 173 
70% of the gene therapy clinical trials for various conditions carried out so far have used modified 174 
viruses to deliver genes [55].  175 
 176 
The success of viral gene delivery based vectors is due to the fact that viruses have had millions of 177 
years of evolution to develop highly efficient mechanisms by which to enter cells and deliver their 178 
genetic payload. Viral vectors have been genetically engineered to remove the pathogenic 179 
components and their ability to self-replicate, while maintaining their efficient mechanisms for 180 
entering cells and delivering the inserted therapeutic gene. Given the diversity of disease targets that 181 
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are potentially amenable to gene transfer, different viral vectors have been developed to suit 182 
particular applications. These include adenovirus, adeno-associated virus (AAV) and lentivirus. Ideal 183 
characteristics of a viral vector include the abilities to be reproducibly and stably produced and 184 
purified to high titres, to mediate targeted delivery and transgene expression without inducing 185 
harmful side effects [56].  186 
 187 
Lentiviral vectors can be regarded as the current gold standard in experimental gene therapy for 188 
peripheral nerve repair [57]. This may be attributed to several factors. Firstly, a precedent for using 189 
lentiviral vectors has been set in clinical trials. Lentiviral vectors have been used in a range of 190 
successful life-saving gene therapy clinical trials for a number of conditions such as X-linked severe 191 
combined immunodeficiency [58] and X-linked adrenoleukodystrophy [49]. Secondly, Schwann cells 192 
are rapidly dividing in the context of PNI. Lentiviruses offer stable expression in dividing cells [59] and 193 
can therefore potentially ensure a continuous provision of neurotrophic factors, thus maintaining the 194 
pro-regenerative environment needed for peripheral nerve regeneration. This is because they have 195 
the ability to integrate the transgene into the host cell’s genome so when cells divide, all progeny 196 
also carry a copy of the therapeutic gene. Thirdly, choosing the right viral vector for the target cell 197 
type is essential to ensure transduction efficiency. AAV serotypes differ dramatically in their ability to 198 
target various tissues and cell types and careful selection of the serotype is required for successful 199 
transduction [57]. On the other hand, the host cell range of lentiviral vectors can be expanded or 200 
altered by modifying the viral envelope [60].  201 
 202 
5. Enhancing the microenvironment following nerve injury 203 
Further to guiding axonal growth and providing support cells, nerve repair devices are also 204 
increasingly being used as a carrier for the delivery of substances which enhance the 205 
microenvironment following injury. Due to the short half-life of many of these substances as well as 206 
side effects when administered systemically, strategies for continuous local release have been 207 
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developed. These include loaded crosslinked polymer scaffolds [61] and incorporation of loaded 208 
microspheres into the scaffold [62]. An alternative for the local and continuous release of substances 209 
required for peripheral nerve regeneration is gene therapy. Original full length journal articles 210 
investigating the combined use of gene therapy and stem cells for peripheral nerve tissue 211 
engineering published in English from 2006 to 2016 were searched for this review. Relevant articles 212 
were identified and obtained from the online database PubMed between April and October 2016. 213 
The following search strategy was used (stem cells OR stem cell OR cell therapy) AND (gene therapy 214 
OR gene delivery) AND (peripheral nerve injury OR peripheral nerve repair OR peripheral nerve 215 
regeneration). 366 articles were identified. The duplicates were removed manually. Only the studies 216 
which met the following inclusion criteria were included: (1) in vivo experimental studies in animals, 217 
(2) nerve gap injuries and (3) the use of a nerve conduit or graft as a scaffold for the delivery of 218 
therapeutic cells. These criteria were chosen for the following reasons. (1) Animal models are crucial 219 
for assessing biocompatibility, tissue response and mechanical function of nerve repair devices prior 220 
to clinical translation [63]. (2) Models of nerve crush were not included because tissue engineering is 221 
not used to repair the damage associated with these types of injuries. (3) This review focuses on a 222 
tissue engineering approach to peripheral nerve regeneration, so studies which used direct injection 223 
into the injury site as a mode of delivery of the therapeutic cells were excluded.    224 
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Table 1: Studies enhancing the regenerative potential of therapeutic cells by over expression of neurotrophic factors. 225 
Author Gene delivery 
method 
Gene(s) Cell type Mode of delivery Animal model 
(length of gap, 
duration of 
experiment) 
Outcome measures 
Man et al., 2016 
[64] 
Lentivirus VEGF Human bone marrow 
stem cells 
Cells in fibrin gel 
seeded in a poly-L-
lactide acid conduit 
Mouse sciatic 
transection (4mm 
gap, 2 weeks)  
Neurite extension, 
Schwann cell 
proliferation, VEGF 
expression, axon 
regeneration, stem 
cell tracking 
Marquardt et al. 
(2015) [65] 
Lentivirus GDNF Rat Schwann cells Acellular nerve 
allografts and cells 
injected into the 
distal nerve stump 
Rat sciatic nerve 
transection (30mm 
gap, up to 8 weeks) 
Total axon count, 
axon density,  
fibre width, 
myelination, 
percent neural 
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tissue, live tracking 
of regenerating 
axons 
Tseng et al. (2014) 
[66] 
Effectene®-based 
transfection 
BDNF Rat adipose derived 
stem cells 
Cell spheroids 
seeded in a 
poly(D,L-lactide) 
conduit 
Rat sciatic nerve 
transection (10mm 
gap, 31 days) 
Electrophysiology, 
cell tracking, cross-
sectional area of 
regenerated axons, 
quantification of 
axonal growth 
Liu et al., 2014 [67] Lentivirus CDNF Rat bone marrow 
stem cells 
Cells in a collagen 
conduit 
Rat sciatic nerve 
transection (5mm 
gap, up to 12 
weeks) 
Protein expression, 
walking track 
analysis, muscle 
mass, horseradish 
peroxidase tracing, 
myelination 
thickness, axon 
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diameter, G-ratio 
Allodi et al., 2014 
[68] 
 
Lentivirus FGF-2 Rat Schwann cells Cells in collagen 
matrix seeded in a 
silicone conduit 
Rat sciatic 
transection (6mm 
gap, up to 2 
months)  
 
Protein expression, 
immunohistochemi
stry, 
electrophysiology, 
axon regeneration, 
myelination, 
functional recovery 
Godinho et al., 
2013 [69] 
 
Lentivirus  
 
BDNF, CNTF, NT3  
 
Rat Schwann cells Cells in culture 
media injected into 
an acellular nerve 
sheath  
Rat peroneal 
transection (10mm 
gap, 10 weeks)  
 
Quantification of 
axonal numbers, 
functional recovery, 
axonal 
regeneration, 
myelination, 
immunohistochemi
stry  
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Santosa et al., 2013 
[70] 
Lentivirus  
 
GDNF  
 
Rat Schwann cells Cells in culture 
media seeded in an 
acellular nerve 
allograft 
Rat sciatic 
transection (14mm 
gap, up to 12 
weeks)  
 
Gene expression, 
electrophysiology, 
total myelinated 
fibre count and 
fibre width, percent 
neural tissue, 
muscle mass 
Shakhbazau et al., 
2013 [71] 
 
Lentivirus  
 
GDNF Rat Schwann cells Silicone conduit and 
cells injected into 
the distal nerve 
stump 
Rat sciatic 
transection (5mm 
gap, up to 11 
weeks) 
 
Electrophysiology, 
sensitivity testing, 
motor recovery, 
muscle mass 
Fu et al. (2011) [72] Polyfect®-based 
transfection  
BDNF, GDNF Mouse neural stem 
cells 
Cells in culture 
media seeded in a 
poly(D,L-lactide) 
conduit 
Rat sciatic nerve 
transection (15mm 
gap, 8 weeks) 
Functional gate 
analysis, 
electrophysiology, 
cross-sectional area 
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of regenerated 
nerve, numbers of 
myelinated sheaths 
and blood vessels 
Fang et al. (2010) 
[73] 
Electroporation CNTF Schwann  cell  line  
(CRL-2764) 
Cells in culture 
media seeded in a 
poly(lactic-co- 
glycolic 
acid)/chitosan 
conduit 
Rat optic nerve 
transection (3mm 
gap, up to 8 weeks) 
Quantification of 
axonal growth, 
length of 
regenerated axons, 
inflammatory 
response in the 
grafts 
Shi et al. (2009) [74] Lentivirus GDNF Rat neural stem cells Cells in Matrigel 
seeded in a 
polyglycolic/polygly
colic   acid conduit 
Rat facial nerve 
transection (8mm 
gap, up to 12 
weeks) 
Electrophysiology, 
number of  
regenerated  axons, 
myelin thickness 
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Haastert et al. 
(2006) [75] 
Metafectene®-
based transfection 
 
FGF-2 Rat Schwann cells Cells in culture 
media seeded in a 
silicone conduit 
Rat sciatic nerve 
transection (15mm 
gap, up to 6 
months)  
 
Cell tracing, analysis 
of protein 
expression, 
functional recovery, 
electrophysiology, 
retrograde labelling 
of regenerated 
neurons, 
quantification of 
myelinated nerve 
fibres 
Li et al. (2006) [76] Retrovirus GDNF Rat Schwann cells Cells in culture 
media seeded in a 
silicone conduit 
Rat sciatic nerve 
transection (10mm 
gap, up to 16 
weeks) 
Protein and gene 
expression, 
immunochemistry, 
electrophysiology, 
density of 
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myelinated nerve 
fibres, myelin 
sheath thickness, 
nerve cross-
sectional area 
Abbreviations: VEGF: vascular endothelial growth factor, GDNF: glial cell-derived neurotrophic factor, BDNF: brain-derived neurotrophic factor, CDNF: 226 
conserved dopamine neurotrophic factor, FGF-2: basic fibroblast growth factor, CNTF: ciliary neurotrophic factor, NT-3: neurotrophin-3.227 
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Table 1 highlights that only the overexpression of neurotrophic factors in therapeutic cells delivered 228 
via conduits has been encountered in literature. Neurotrophic factors are key nervous system 229 
regulatory proteins that modulate neuronal survival, axonal growth, synaptic plasticity and 230 
neurotransmission [77]. However, for the sake of completeness and its inherent interest, gene 231 
therapy has also been used to deliver transcription factors to the injured peripheral nervous system 232 
[78]. This study does not meet the inclusion criterion (3) mentioned above and will not be discussed 233 
further.  234 
 235 
As mentioned earlier, lentiviral vectors are considered to be the current gold standard in 236 
experimental gene therapy for peripheral nerve regeneration [57]. Studies which make use of this 237 
vector are discussed in this section. Allodi et al. (2014) [68] implanted a silicone tube containing 238 
Schwann cells transduced with a lentiviral vector encoding basic fibroblast growth factor (FGF-2) in a 239 
model of rat sciatic nerve injury. Electrophysiological tests conducted for up to two months after 240 
injury revealed accelerated and more marked reinnervation of hindlimb muscles in the treated 241 
animals, with an increase in the number of motor and sensory neurons that reached the distal tibial 242 
nerve. Improvement in regeneration was also reported by Godinho et al. (2013) [69], who used 243 
acellular nerve grafts seeded with lentiviral transduced Schwann cells expressing brain-derived 244 
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF) or neurotrophin-3 (NT-3) in a model of 245 
rat peroneal nerve injury. Treated animals showed an increase in the number and type of 246 
regenerating axons, an increase in myelination and improved locomotor function. The lentiviral-247 
modified Schwann cells remained viable in the grafts for many weeks and could be used as vehicles 248 
to provide sustained delivery of transgene-derived factors to the injured nerve. These studies 249 
confirm the potential usefulness of developing combined gene and cell therapy for peripheral nerve 250 
repair. 251 
 252 
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While the transplantation of Schwann cells overexpressing neurotrophic factors in animal models of 253 
PNI has generally improved regeneration, some studies have reported otherwise. Santosa et al. 254 
(2013) [70] supplemented an acellular nerve allograft with lentiviral transduced Schwann cells 255 
overexpressing glial cell-derived neurotrophic factor (GDNF) and assessed nerve regeneration and 256 
functional recovery in a rat model of sciatic nerve injury.  GDNF has been shown to promote survival 257 
of motor neurons following injury [79]. However, in the study by Santosa et al. (2013) [70] the 258 
treated group produced fewer myelinated fibres with smaller diameter and less neural tissue at the 259 
distal end of the graft compared to controls. This was attributed to the “candy store effect”, where 260 
the constant release of GDNF by the Schwann cells in the graft caused a bundling of axons in the 261 
mid-graft area and prevented regenerating axons from reinnervating the target organ. This effect 262 
was also previously observed by Tannemaat et al. (2008b) [80], who reported that overexpression of 263 
GDNF caused trapping of regenerating axons, and impaired axonal outgrowth and reinnervation of 264 
target muscles.  265 
 266 
The studies by Santosa et al. (2013) [70] and Tannemaat et al. (2008b) [80] suggest that the 267 
overexpression of neurotrophic factors should be executed carefully. Tannemaat et al. (2008b) [80] 268 
proposed that the “candy-store effect” may have been caused by the large increase in GDNF 269 
expression as a previous study by Piquilloud et al. (2007) [81] had revealed that the trapping of 270 
regenerating axons by GDNF seemed to be dose dependent. Therefore, regeneration may still be 271 
enhanced through careful control of GDNF elevation, which may be achieved through the use of viral 272 
vectors with regulatable transgene expression [82, 83]. Marquardt et al. (2015) [65] investigated the 273 
optimal duration of GDNF expression in a rat model of sciatic nerve injury. GDNF release was 274 
regulated through transduction of Schwann cells with a tetracycline-inducible GDNF overexpressing 275 
lentiviral vector. The cells were transplanted in acellular nerve allografts. Doxycycline was 276 
administered for 4, 6 or 8 weeks. Live imaging and histomorphometric analysis determined that 6 277 
weeks of doxycycline treatment resulted in enhanced regeneration compared to 4 or 8 weeks. GDNF 278 
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expression for only 4 weeks resulted in poor axon extension whereas expression for 8 weeks 279 
resulted in axon trapping. These results are in line with findings by Shakhbazau et al. (2013) [71], 280 
who had also used a tetracycline-inducible system to show that Schwann cell-based GDNF therapy 281 
can increase the extent of axonal regeneration while controlled deactivation of GDNF prevents 282 
trapping of regenerating axons in GDNF-enriched areas.  283 
 284 
Interestingly, lentiviral mediated genetically modified Schwann cells overexpressing neurotrophic 285 
factors have also been successfully used in models of spinal cord injury. Schwann cell transplantation 286 
into the injured spinal cord provides a neuroprotective effect, promotes axonal regeneration and 287 
myelination and may increase sensory and motor functions [84]. The use of gene therapy to enhance 288 
Schwann cells may further enhance these outcomes. Do-Thi et al. (2015) [85] implanted a guidance 289 
channel seeded with lentiviral transduced Schwann cells overexpressing GDNF in a rat spinal cord 290 
injury model of lateral hemisection at thoracic level.  Axonal growth was superior in rats treated with 291 
the transduced Schwann cells. Deng et al. (2013) [86] also transplantated lentiviral transduced 292 
Schwann cells overexpressing GDNF in semipermeable polyacrylonitrile/polyvinyl chloride copolymer 293 
guidance channels into a rat model of spinal cord hemisection at thoracic level. Axon regeneration 294 
extended through the lesion gap and the regenerated axons formed synapses with host neurons, 295 
resulting in restoration of action potentials and partial recovery of function. 296 
 297 
Although the inclusion of Schwann cells in nerve repair devices has been shown to improve 298 
regeneration following both peripheral nerve injury and spinal cord injury, their use in these 299 
applications is limited by difficulties in harvesting and expansion. There is an increasing trend in the 300 
transplantation of genetically modified stem cells to replace the use of Schwann cells. Shi et al. 301 
(2009) [74] transplanted a polyglycolic/polyglycolic acid nerve conduit seeded with lentiviral 302 
transduced rat neural stem cells overexpressing GDNF into a rat model of facial nerve injury. The 303 
implanted neural stem cells exhibited sustained and significant GDNF expression following 304 
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implantation. Nerve action potential amplitude, axonal area and axonal number were significantly 305 
greater in the animals treated with the transduced neural stem cells compared to the animals 306 
treated with control untransduced cells. Additionally, some of the transplanted cells were positive 307 
for S100, a Schwann cell marker, suggesting that the neural stem cells may differentiate down a 308 
Schwann cell lineage.  309 
 310 
6. Conclusion 311 
The present review evaluated the novel experimental strategy of combining gene and cell therapy in 312 
the context of PNI. Seeding nerve repair devices with optimised therapeutic cells that maintain the 313 
appropriate repair Schwann cell phenotype may provide the optimal environment for axonal 314 
regeneration and re-establishment of functional circuits following PNI, leading to improved patient 315 
outcomes. While translation of cellular tissue-engineered constructs towards clinical application in 316 
PNI is still in its infancy, it has substantial therapeutic potential for treating nerve damage in the near 317 
future. 318 
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